Global R&D Pipeline
My Favorite
Hot Targets:
PD-L1
Back
Total number of drugs
857
Phase II and later clinical stages
6.3%
Involving companies
916
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) | Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) | Bispecific antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | PDL1 inhibitors TGF-β inhibitors | Wuhan YZY Biopharma Co., Ltd. | Huazhong University of Science & Technology Wuhan YZY Biopharma Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Recombinant anti-PD-L1/TGF-β bispecific antibody (Wuhan YZY Biopharma) | - | - | detail > | |
| Danburstotug | Danburstotug | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | PDL1 inhibitors ADCC Immunomodulators | Sorrento Therapeutics, Inc. | Seoul National University Hospital Immuneoncia Therapeutics, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | Danburstotug | - | - | detail > | |
| PD-L1 t-haNK(National Cancer Institute) | PD-L1 t-haNK(National Cancer Institute) | Gene therapy | Neoplasms | PDL1 modulators | National Cancer Institute | National Cancer Institute | Phase 2 | - | - | - | - | - | - | - | - | - | PD-L1 t-haNK(National Cancer Institute) | - | - | detail > | |
| PDL1-t-haNK (ImmunityBio) | PDL1-t-haNK (ImmunityBio) | Natural Killer Cell Therapies | Neoplasms Infectious Diseases Nervous System Diseases Congenital Disorders Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | PDL1 modulators | NantKwest, Inc. | ImmunityBio, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | PDL1-t-haNK (ImmunityBio) | - | - | detail > | |
| QL-301 | QL-301 | Bispecific antibody | Neoplasms Hemic and Lymphatic Diseases | 4-1BB agonists PDL1 inhibitors | Qlsf Biotherapeutics, Inc. | Qlsf Biotherapeutics, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | QL-301 | - | - | detail > | |
| HLX-301 | HLX-301 | Bispecific antibody | Neoplasms | PDL1 inhibitors TIGIT inhibitors | Shanghai Henlius Biopharmaceuticals Co. , Ltd. | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | HLX-301 | - | - | detail > | |
| FH-2001 | FH-2001 | Small molecule drug | Neoplasms | FGFRs antagonists PDL1 inhibitors VEGFR antagonists | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | NovaOnco JS Therapeutics Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | FH-2001 | - | - | detail > | |
| Durvalumab/Gefitinib | Durvalumab/Gefitinib | Small molecule drug Monoclonal antibody | Neoplasms Respiratory Diseases | EGFR antagonists PDL1 inhibitors | MedImmune LLC | MedImmune LLC | Phase 2 | - | - | - | - | - | - | - | - | - | Durvalumab/Gefitinib | - | - | detail > | |
| IMM-2505 | IMM-2505 | Bispecific antibody | Neoplasms | CD47 inhibitors PDL1 inhibitors | ImmuneOnco Biopharmaceuticals (Shanghai), Inc. | Sunho (China) Biopharmaceutical Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | IMM-2505 | - | - | detail > | |
| Recombinant anti-human CD47/PD-L1 bispecific antibody(Innovent Biologics) | Recombinant anti-human CD47/PD-L1 bispecific antibody(Innovent Biologics) | Bispecific antibody | Neoplasms Respiratory Diseases Hemic and Lymphatic Diseases Immune System Diseases Other Diseases | CD47 inhibitors PDL1 inhibitors | Innovent Biologics (Suzhou) Co. Ltd. | Hunan Cancer Hospital Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Recombinant anti-human CD47/PD-L1 bispecific antibody(Innovent Biologics) | - | - | detail > |
Total 857 data
1
2
3
4
5
6
...
85
86
